Business
CNS Announces Highlights from Annual Meeting of Shareholders
HOUSTON, June 9, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"HOUSTON, June 9, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced highlights from its 2020 Annual Meeting of Shareholders. \n\n \n \n \n \n \n \n\n \nOn June 8th 2020, CNS held its Annual Meeting of Shareholders. A total of 13,254,656 shares voted, representing over 80% of the total shares outstanding. All five board members up for re-election, including John Climaco, George Gumulka, Jeffry R. Keyes, Andrzej Andraczke, and Carl Evans, were re-elected with over 99.6% of votes in favor and no votes against. The Company's two additional proposals were passed with limited opposition, receiving over 98% votes in favor.\nAbout CNS Pharmaceuticals, Inc.\nCNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of GBM, an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has been shown in preclinical studies to be 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, please visit www.cnspharma.com. \nForward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Se...